Therefore, an agonistic mAb targeting co-stimulating receptor OX40 on T cells, one of the most promising targets, could promote an antitumor immune response by inducing tumor anti-specific CD8+ T-cell responses and decreasing immunosuppressive regulatory T cells in vivo (Ruby et al. 2007). The gene discussed is TNFRSF4; the disease is neoplasm.